SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
--------------
FORM 8-K
Current Report Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 29, 2003
BENTLEY PHARMACEUTICALS, INC.
--------------------------------------------------------------------------------
(Exact Name of Registrant as Specified in Charter)
Delaware 1-10581 59-1513162
--------- -------- ----------
(State or Other Jurisdiction (Commission (IRS Employer
of Incorporation) File No.) Identification No.)
Bentley Park; 2 Holland Way; Exeter, New Hampshire 03833
--------------------------------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (603) 658-6100
65 Lafayette Road, 3rd Floor, North Hampton, New Hampshire 03862
--------------------------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
------ ------------------------------------------------------------------
(c) Exhibits:
99.1 Press Release of the Registrant dated April 29, 2003.
Item 9. Regulation FD Disclosure.
------ -------------------------
On April 29, 2003, Bentley Pharmaceuticals, Inc. (the "Registrant") issued the
press release attached to this Current Report on Form 8-K (the "Report") as
Exhibit 99.1 reporting its financial results for the three months ended March
31, 2003, which is incorporated herein by reference.
The information in this Report, including the exhibit, is furnished pursuant to
Item 9 and shall not be deemed to be "filed" for the purposes of Section 18 of
the Securities Exchange Act of 1934, as amended, or otherwise subject to the
liabilities of that Section. It shall not be deemed incorporated by reference in
any filing under the Securities Act of 1933, as amended, except as shall be
expressly set forth by specific reference in such a filing.
The foregoing information is furnished under Item 9 in place of Item 12 of this
Report in accordance with the interim guidance provided by the Securities and
Exchange Commission in Release 33-8216 dated March 27, 2003.
SIGNATURES
----------
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
BENTLEY PHARMACEUTICALS, INC.
Date: April 29, 2003 By: /s/ MICHAEL D. PRICE
--------------------
Michael D. Price
Vice President and
Chief Financial Officer
EXHIBIT INDEX
Exhibit
Number Description
------- -----------
99.1 Press Release of the Registrant dated April 29, 2003.